Minneapolis study shows hint of steroid benefit following AF ablation

[Heartwire, May 25, 2010] Researchers at the Minneapolis Heart Institute at Abbott Northwestern are excited about a small study known as the Steroid after Ablation (SAAB) trial, lead by Dr. Daniel Melby, a cardiologist with the Minneapolis Heart Institute at Abbott Northwestern. Interim results showed that steroid therapy following the ablation of atrial fibrillation (AF) resulted in a nonsignificant trend toward reduction of early AF symptoms.

The results of the study, were presented May 14 in Denver, Colo. during the late-breaking clinical-trials session at the Heart Rhythm Society 2010 Scientific Sessions.